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Available online 20 October 2011Collectin 11 (CL-11), also referred to as collectin kidney 1 (CL-K1), is a pattern recognition
molecule that belongs to the collectin group of proteins involved in innate immunity. It inter-
acts with glycoconjugates on pathogen surfaces and has been found in complex with
mannose-binding lectin-associated serine protease 1 (MASP-1) and/or MASP-3 in circulation.
Mutation in the CL-11 gene was recently associated with the developmental syndrome 3MC. In
the present study, we established and thoroughly validated a sandwich enzyme-linked immu-
nosorbent assay (ELISA) based on two different monoclonal antibodies. The assay is highly
sensitive, specific and shows excellent quantitative characteristics such as reproducibility, di-
lution linearity and recovery (97.7–104%). The working range is 0.15–34 ng/ml. The CL-11 con-
centration in two CL-11-deficient individuals affected by the 3MC syndrome was determined
to be below 2.1 ng/ml. We measured the mean serum CL-11 concentration to 284 ng/ml in
100 Danish blood donors, with a 95% confidence interval of 269–299 ng/ml. There was no sig-
nificant difference in the CL-11 concentration measured in matched serum and plasma sam-
ples. Storage of samples and repeated freezing and thawing to a certain extent did not
influence the ELISA. This ELISA offers a convenient and reliable method for studying CL-11
levels in relation to a variety of human diseases and syndromes.
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;molecules structurally characterized by containing a carbohy-
drate recognition domain and a collagen-like region (Keshi et
al., 2006). CL-11 is ubiquitously expressed, but highest levels
are found in the adrenal glands, the kidneys, and the liver,
and it is also present in circulation (Hansen et al., 2010). It is
highly conserved among species ranging from zebrafish to
humans. CL-11 has been shown to bind to intact bacteria, fungi
and influenza A virus, and also to decrease influenza A infectivi-
ty. CL-11 was found to be associated with mannose-binding
lectin-associated serine protease 1 (MASP-1) and/or MASP-3 in
plasma (Hansen et al., 2010). These findings indicate a role for
CL-11 in the defense against pathogens and in the activation of
the complement system. Recently, CL-11 and MASP-3 were
shown to be involved in fundamental developmental processes.
Individuals with mutations in genes encoding either of the two
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known as the 3MC syndrome (Rooryck et al., 2011).
Variations in serum levels of collectins have been impli-
cated in various immunity disorders. Functional mannose-
binding lectin (MBL) deficiency, caused by single-nucleotide
polymorphisms in the coding region of the MBL2 gene, has
been associated with increased susceptibility to infections in
young children and immunocompromised individuals (Sumiya
et al., 1991; Garred et al., 1997; Summerfield et al., 1997; Neth
et al., 2001; Peterslund et al., 2001).MBL deficiency or lowMBL
serum levels are also associatedwith the occurrence of autoim-
mune disorders, such as systemic lupus erythematosus (SLE)
(Lee et al., 2005). Circulatory levels of the otherwise lung-
associated collectin surfactant protein D (SP-D) are increased
upon lung injuries (Leth-Larsen et al., 2003). Low serum levels
of SP-D, caused by the variant allele Thr11, may increase sus-
ceptibility to tuberculosis (Floros et al., 2000). Low serum levels
of SP-D have also been implicated in pathogenesis of SLE
(Hoegh et al., 2009).
In order to identify the biological functions of CL-11, it is
necessary to be able to measure CL-11 levels in serum and
other fluids. The objectives of the present work were to de-
velop and validate an enzyme-linked immunosorbent assay
(ELISA) for measuring human CL-11 in various samples, and
to determine CL-11 levels in normal serum and plasma.
2. Materials and methods
2.1. Reagents and buffers
Unless otherwise stated, reagents were obtained from
Sigma-Aldrich (Vallensbaek, Denmark). The following buffers
were used: TBS: (10 mM Tris and 145 mM NaCl, pH 7.4),
coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6),
washing buffer for ELISA (TBS, 5 mM EDTA, 0.05% Emulfogen,
pH 7.4), substrate buffer (35 mM citric acid, 67 mMNa2HPO4,
0.012% H2O2, pH 5.0), washing buffer for Western blotting
(TBS, 5 mM EDTA, 0.1% Emulfogen, 5% non-fat dried milk,
0.1% w/v BSA, pH 7.4).
2.2. Expression and puriﬁcation of recombinant CL-11
The expression and purification of recombinant CL-11 were
performed as previously described (Hansen et al., 2010). Briefly,
full-length untagged human CL-11was expressed in DG44 CHO
cells using the bicistronic pOptiVEC TOPO vector (Invitrogen,
Taastrup, Denmark). Recombinant CL-11 was purified from
the culture supernatant using mannose-Sepharose affinity
purification. The concentration of CL-11 was measured by
quantitative amino acid analysis of 7 different fractions of
purified CL-1 from three different rounds of purification. The
derived average conversion factor of the 7 analyses was used
throughout the study.
2.3. Anti-CL-11 MAbs
Monoclonal antibodies (MAbs) were essentially produced
by the principles described by Kohler and Milstein (Kohler
andMilstein, 1975) in outbred NMRI mice with modifications
previously described (Hansen et al., 2008). Briefly, purified
recombinant CL-11 was used as the antigen. Positive cloneswere identified by ELISA using microtiter plates coated with
CL-11. Cells from the positive wells were cloned at least
four times by limiting dilution. For MAb production and sub-
sequent purification, hybridomas were grown and allowed to
express the MAbs in Hybridoma-SFM with 0.75% ultra-low
IgG fetal bovine serum (both from Invitrogen). MAbs were
purified by means of affinity chromatography using a HiTrap
Protein GHP column (GEHealthcare, Piscataway, NJ USA) under
previously described conditions (Akerstrom and Bjorck, 1986).
MAbs were biotinylated using biotin N-hydroxysuccinimide
ester according to themanufacturer's recommendations. Briefly,
purified antibodies were dialyzed against 0.1 M carbonate buff-
er, pH 8.5, and biotin N-hydroxysuccinimide ester was added
corresponding to 1/6 (w/w) of the total protein amount. The
mixture was incubated with gentle mixing for 4 h at room tem-
perature. Unreacted biotinylation reagent was removed by dial-
ysis against TBS, pH 7.4.
2.4. SDS-PAGE and Western blotting
Proteins were separated by SDS-PAGE in 4–12% Novex Bis-
Tris gels (Invitrogen) and blotted onto polyvinylidene difluoride
membranes (PVDF HyBond, Amersham Biosciences, Little
Chalfont, UK). The membranes were washed and blocked
for 1 h in washing buffer, followed by overnight incubation
at 4 °C with biotinylated primary MAbs (0.52 μg/ml of 11–2,
1.0 μg/ml of 14–29 or 1.0 μg/ml of isotype-matched (IgG1κ)
control anti-mouse SP-D K403) diluted in washing buffer.
After repeated washing, the membranes were incubated for
1 h at room temperature in horseradish peroxidase (HRP)-
conjugated Streptavidin (Invitrogen) diluted to 1/10,000 in
washing buffer. The membranes were washed and developed
with aminoethyl carbazol.
2.5. ELISA for CL-11 and assay optimization
Polystyrene microwell plates (Maxisorp, Nunc, Roskilde,
Denmark) were coated with 5 μg MAb 11–2 per ml coating
buffer (100 μl/well). After overnight incubation at 4 °C, the
coated wells were washed three times and left to block with
washing buffer for 30 min at room temperature. The calibrator,
controls and samples were diluted in washing buffer contain-
ing bovine serum (0.1% v/v; AH diagnostics, Aarhus, Denmark)
and heat-aggregated human IgG (50 μg/ml; Innovative Re-
search, Novi, MI, USA) and incubated overnight at 4 °C. Subse-
quently, the wells were washed three times and biotinylated
MAb 14–29 diluted to 0.5 μg/ml in washing buffer containing
BSA (1 mg/ml) was added to the wells and incubated for 1 h
at room temperature. After three washes, HRP-conjugated
Streptavidin diluted to 1/12,000 in washing buffer containing
BSA (1 mg/ml) was added to the wells and incubated for
30 min at room temperature. The wells were washed three
times and 0.4 mg of o-phenylene-diamine (Kem-En-Tec,
Taastrup, Denmark) was added per ml substrate buffer. After
15 min the color development was stopped with 1 M H2SO4.
Optical density (OD) was measured at 490–650 nm using
Vmax Kinetic Microplate Reader and the data were processed
using SoftMax Pro software (Molecular Devices, Wokingham,
United Kingdom). The samples were diluted to 1/40 and the
calibrator, quality controls (QCs) and samples were run in trip-
licates unless otherwise stated. Optimal dilutions of MAb 11–2
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checkerboard titrations of the dilution of one MAb against
the dilution of plasma. The optimal concentration of HRP-
conjugated streptavidin was determined in the same way.
2.6. Assay validation
2.6.1. Calibrator and quality controls
The calibrator consisted of the culture supernatant from
DG44 CHO cells expressing recombinant CL-11. A two-fold
serial dilution of the culture supernatant was used to gener-
ate an eight-point calibrator curve with a range from 0.26 to
34.8 ng/ml. A five-parameter fit model was applied to the
calibrating samples and used to estimate the concentration
of unknown samples. The calibrator was stored as single-use
aliquots at −80 °C. The QCs consisted of a pool of serum or
plasma from five healthy volunteers diluted 1/11, 1/80 and 1/
500 in dilution buffer to represent high, medium and low con-
centrations of CL-11, respectively. The QCs were stored as sin-
gle ready-to-use aliquots at−80 °C.
2.6.2. Parallelism
To study parallelism, the calibrator serial dilution curve
was compared to the serial dilution curves of two batches
of purified recombinant CL-11 and serial dilutions curves of
plasma and serum from two blood donors (analyzed in dupli-
cates). OD data were evaluated using regression analysis on
logistically transformed values, an algorithm that comprised
several steps. Due to the maximum limit of the OD determi-
nation, a number of consecutive measurements of OD=4.0
was observed in each dilution series. Only the last value of
OD=4.0 was maintained in each dilution series, while the
prior maximum determinations were omitted. Subsequently,
all OD values were divided by 4.1 to transform the OD data to
values above 0, but below 1, as required for the subsequent
logistic transformation, y′=ln[y/(1−y)]. A background
level of OD=0.05 was observed, and values below the corre-
sponding logistically transformed values were omitted from
further analysis. A linear regression was fitted to the remain-
ing data points and multiple comparisons among slopes
using Tukey's HSD test were used to compare the parallelism
of the different serial dilutions. The statistical analyses were
performed using the Analyse-it software (Analyse-it Soft-
ware, Ltd, Leeds, UK).
2.6.3. Working range and detection limit
Ten two-fold serial dilutions of serum and plasma sam-
ples from five blood donors were analyzed in triplicates. Co-
efficients of variation (CV) were calculated for the triplicate
measurements of each dilution. A “measured/mean” ratio
was expressed for each sample using the triplicate measure-
ments and calculating the mean of the triplicates. To study
linearity, the CL-11 concentration calculated for each dilution
and multiplied by the dilution factor was compared to a
mean of the CL-11 concentration that was back-calculated
from four dilutions of each sample (1/16–1/128 for serum sam-
ples and 1/20–1/160 for plasma samples). The working range
was determined as the CL-11 concentrations for which CV
was b10% and the measured/mean ratios deviated b20%. The
lower detection limit was calculated as the background signal
±2 standard deviations (SD).2.6.4. Recovery
Serum and plasma samples from three healthy volunteers
were diluted to contain different levels of endogenous CL-11
and spikedwith DG44 CHO cell culture supernatant containing
recombinant CL-11. Recovery was calculated as the ratio of
measured CL-11 over the expected total CL-11 concentration.
2.6.5. Intra- and interassay variation
Intraassay variation was calculated by running the QCs in
22 replicates on a single plate. The interassay variation was
determined by running the QCs in triplicates on ten plates on
five separate occasions. Intra- and interassay CVs b10% were
found acceptable.
2.7. Storage temperature and effect of repeated freezing and
thawing
Serum and plasma samples (250 μl aliquots) from five dif-
ferent healthy persons were stored at room temperature, 4 °C
and −20 °C for 1 week. CL-11 levels were measured after
24 h and after 1 week of storage. Furthermore, CL-11wasmea-
sured in samples stored at−20 °C and−80 °C for one month.
The fresh sample aliquots were also subjected to eight freeze-
thaw cycles (−20 °C and room temperature, respectively)
and CL-11 levels were measured after 1, 2, 3, 4 and 8 freeze-
thaw cycles.
2.8. Serum and plasma samples
Matched serum and EDTA-plasma samples collected from
100 Danish blood donors and serum samples from two indi-
viduals affected by 3MC syndrome, who carry a homozygous
mutation in COLEC11 (p.Gly204Ser), were tested in ELISA in
triplicates at a dilution of 1/40 and 1/14, respectively. The
normality of the data was evaluated using the Shapiro–Wilk
test. The Altman–Bland method was used to assess differ-
ences in CL-11 concentrations between the matched serum
and plasma samples. EDTA-plasma from two healthy individ-
uals was depleted for CL-11 by passage through an anti-CL-11
MAbs column (4 different anti-CL-11 MAbs conjugated to
Sepharose) and tested in ELISA in triplicates at a dilution of
1/10 or 1/20.
3. Results
3.1. Characterization of monoclonal antibodies and optimization
of ELISA
The specificity of MAbs 11–2 and 14–29 was analyzed by
Western blotting. To mimic the ELISA setup, bound serum an-
tigens were eluted from microtiter wells coated with MAb
11–2 and analyzed by Western blotting using biotinylated
MAbs 14–29 and 11–2 (Fig. 1A). By this approach, a protein
band of 34 kDa, corresponding to full-length CL-11, was
detected in reduced eluates. The biotinylated MAb 14–29
reacted only weakly with reduced CL-11. Under nonreduced
conditions immunoreactivity bands at 200 and 300 kDa
were detected, corresponding to dimers and trimers of sub-
units of CL-11, as well as several oligomers larger than
300 kDa. In addition, a faint band of approximately 28 kDa
(not detected with MAb 14–29) and a band of approximately
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ates, respectively. These bands also developed with other
anti-CL-11 MAbs (data not shown) and therefore we speculate
that they also represent CL-11 (see discussion). From a panel of
50mouse anti-humanCL-11MAbs recognizing at least sevendif-
ferent epitopes of CL-11,MAb 11–2 and biotinylated 14–29were
chosen for capture and detection, respectively. TheMAbs bind toFig. 1. Characterization of MAbs 11–2 and 14–29 and calibration of the
ELISA. (A) Western blotting of serum preincubated into ELISA wells coated
with MAb 11–2 (10 μg/ml) and eluted with SDS-PAGE loading buffer under
reducing (red.) and non-reducing conditions (non-red.). Blots were devel-
oped with biotinylated MAbs 14–29 (1), 11–2 (2) or the control MAb (3).
(B) A calibrator curve was made of serial dilutions of culture supernatant
from cells expressing recombinant CL-11. It was compared with serial dilu-
tions of two batches of purified recombinant CL-11. The CL-11 concentration
of purified CL-11 was adjusted to best fit with OD values of the calibrator.
The samples were tested in duplicates. (C) To analyze parallelism, a linear
regression was fitted to logistically transformed OD values (R2>0.97 for all
curves) and used for comparisons of the slopes (see Materials and methods).
The logistically transformed OD values are presented in arbitrary units (AU).different epitopes on CL-11 and MAb 11–2 requires the pres-
ence of EDTA for optimal binding activities (data not shown).
Judged by the highest signal-to-noise ratio and maximum
read-out signal, this combination of MAbs resulted in a sand-
wich ELISA with highest sensitivity. The ELISA was further op-
timized in terms of conditions and concentrations of MAb
11–2, biotinylated MAb 14–29, HRP-Streptavdin and additives
(BSA, heat-aggregated IgG and bovine serum; data not shown).
3.2. Validation of ELISA
Parallelism was observed between the serial dilution curves
of the calibrator and two batches of purified recombinant CL-11
(Fig. 1B). Following logistic transformation, the data sets fitted a
linear regressionwith R2>0.97 for all curveswith the slopes be-
tween−0.88 and−0.91 (Fig. 1C). A Tukey's HSD test revealed
that slopes of the serial dilution curves did not differ significantly
fromeach other (pb0.05). A similar analysis of dilution curves of
the calibrator, the serum and the plasma showed also parallel-
ism with slopes between −0.92 and −1.15 that did not differ
significantly (pb0.05; Fig. 2).We also observed satisfactory par-
allelism between dilution curves of the calibrator and serum
from two individuals with rheumatoid arthritis. This confirmed
that the ELISA was free of interference from rheumatoid factors
(data not shown). The working range was based on combinato-
ry evaluation of the coefficient of variation (CV), the measured/
mean ratio and the linearity of the dilution curves for serum and
plasma from 5 blood donors (Fig. 3). CV was acceptable (b10%)
in the range 0.10 ng/ml–17.1 ng/ml and the measured/mean
ratio was acceptable (b20% deviation from mean) in the range
0.04 ng/ml–34.5 ng/ml. The linearity of diluted samples was
found acceptable (b20% deviation from mean) in the range
0.15 ng/ml–34.5 ng/ml. Based on these findings, the working
range of the ELISA was determined to be 0.15–34.5 ng/ml. The
lower detection limitwas found to be 0.01 ng/ml. The intraassay
CVs were determined for both serum- and plasma-derived QCs
and varied between 1.7% and 4.8%. The interassay CVs for
these samples varied between 5.0% and 8.4%. The validation
data are summarized in Table 1. The recovery was assessed by
the ability to recover known amounts of recombinant CL-11.
The assay recovered 97.7–104% of the expected amounts at
working concentrations from 0.26 to 31.3 ng/ml (Table 2).
3.3. Levels of CL-11 in serum and plasma
The CL-11 concentration was determined in matched serum
and plasma samples from 100 Danish blood donors (Fig. 4A).
The mean serum concentration was estimated to 284 ng/ml
with a 95% confidence interval of 269–299 ng/ml and a range
of 146–497 ng/ml. There was no significant difference in the
CL-11 levels between matched serum and plasma samples
(p=0.15; Fig. 4B). Upon log transformation of data, CL-11
levels in serum and plasma followed a normal distribution
(p=0.62 for serum and p=0.81 for plasma; data not shown).
Using the normally distributed data, we found no significant
difference in CL-11 levels between males and females (data
not shown). The CL-11 concentration in serum from two CL-
11-deficient individuals was below the lower working limit of
the assay. Thus, the CL-11 concentration in these sera was
lower than 2.1 ng/ml when the dilution of the samples was
taken into account (Fig. 4A). Similar observations were made
Fig. 2. Validation of ELISA: parallelism between the calibrator and the sam-
ples. (A) Comparison of the calibrator curve with serially diluted serum
and plasma samples. The CL-11 concentration in serum and plasma was ad-
justed to best fit with OD values of the calibrator. The samples were tested in
duplicates and the analysis is representative of comparison with samples
from two donors. (B) Regression analysis on logistically transformed OD
values (R2>0.95 for all curves) was performed and used for comparisons
of the slopes (see Materials and methods). The logistically transformed OD
values are presented in arbitrary units (AU).
Fig. 3. Validation of ELISA: precision and linearity analysis. Serial dilutions o
serum and plasma samples from five blood donors were analyzed in tripli-
cates. (A) The measured/mean concentration ratio as a function of CL-11
concentration. The range of 0.04–34.5 ng/ml corresponds to an acceptable
deviation of b20%. (B) The CV(%) as a function of CL-11 concentration. The
range of 0.10–34.5 ng/ml corresponds to an acceptable CV ofb10%. (C) The
linearity of CL-11 concentrations. The range of 0.15–134.5 ng/ml corre-
sponds to an acceptable deviation of b20%.
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anti-CL-11 MAb columns.
3.4. Effect of storage and freezing and thawing
The stability of CL-11 in serum and plasma upon storage at
different temperatures was examined using matched serum
andplasma samples from five blood donors. Storage of the sam-
ples for up to 1 week at room temperature, 4 °C or−20 °C did
not affect the concentration of CL-11 significantly. The CL-11
concentration was not influenced by up to eight freeze/thaw
cycles (data not shown).
4. Discussion
A quantitative sandwich CL-11 ELISA was developed using
two different MAbs and using culture supernatant containing
recombinant CL-11 as the calibrator. The current ELISA was
thoroughly validated and appears very reliable and robust.
Our validation is summarized in Tables 1 and 2, and based on
our observations, the ELISA is unaffected by the presence of
rheumatoid factors or differences in storage conditions of sam-
ples. The ELISA allows also measured serum and plasma con-
centrations to be directly compared with each other. Wefobserved excellent parallelism between our calibrator made of
recombinant CL-11 and plasma and serum samples in all our
experiments. We have previously estimated the mean CL-11
concentration to approximately 2 μg/ml in the plasma of 10
healthy individuals based on an absolute correlation with
OD280 measurements of purified recombinant CL-11 (Hansen
et al., 2010). Our quantitative amino acid analysis in present
work showed that this was highly overestimated, most likely
due to the presence of glycosides that influences the absor-
bance measurements (not shown). Due to this discrepancy,
seven different quantitative amino acid analyses were per-
formed, and the average of these was used for final correlation
to absolute concentrations. Antibody specificities were tested
by means of Western blotting and we observed only immuno-
reactivity with bands that we expect to be CL-11. We speculate
Table 2
Assay validation recovery.
Sample source Serum Plasma Serum Plasma Serum
Sample with CL-11 (ng/ml) 31.3 (±0.30) 26.3 (±0.59) 5.86 (±0.12) 1.23 (±0.01) 0.26 (±0.01)
Spiking with CL-11 (ng/ml) 3.58 (±0.02)a 3.62 (±0.03)a 3.58 (±0.02)a 3.62 (±0.03)a 3.62 (±0.03)a
Expected (ng/ml) 34.9 29.9 9.44 4.85 3.88
Measured (ng/ml) 35.0 (±1.03) 30.1 (±0.45) 9.22 (±0.05) 4.77 (±0.05) 4.05 (±0.03)




Serum QC Plasma QC
32.5 ng/ml 3.74 ng/ml 0.54 ng/ml 28.3 ng/ml 3.34 ng/ml 0.60 ng/ml
Intraassay var. CV (%)a 3.2 1.7 2.5 4.8 3.6 3.8
Intraassay var. CV (%)b 7.7 6.6 7.0 5.8 5.0 8.4
Working range (ng/ml) 0.15–34.5
Detection limit (ng/ml) 0.01
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160 kDa, in the reduced and nonreduced eluate, respectively,
represent the reported CL-11 isoforms that lack parts of the
collagen-like region (Keshi et al., 2006) or degraded CL-11Fig. 4. Assessment of CL-11 levels. (A) The CL-11 concentration was measured
in matched serum and plasma samples from 100 Danish blood donors. The
mean serum CL-11 level is 284 ng/ml with a 95% confidence interval of
269–299 ng/ml. The mean CL-11 levels in serum and plasma are indicated
with a solid line. CL-11 concentrations in serum from 3MC syndrome affected
individuals (CL-11 defic.) and in CL-11-depleted plasma (CL-11 depl.) were
below the lower working limit of the assay (corresponding to b2.1 ng/ml).
(B) Correlation between serum and plasma CL-11 levels in the donors. The
solid line indicates the line of identity (x=y).(Fig. 1A). Nonreduced, CL-11 appears to be made of dimers
(200 kDa), trimers (300 kDa) and several multimers of sub-
units larger than the trimers (>300 kDa). In comparison, previ-
ous analysis of recombinant CL-11 showed only the presence of
dimers of subunits (Hansen et al., 2010), but judged from the
careful studies of parallelism the discrepancy appears not to in-
fluence the ELISA. The specificity of the assay was further dem-
onstrated by showing that the CL-11 concentration in serum
from two individuals affected by 3MC syndrome was below
the lower working limit of the assay. Thus, the levels in these
individuals are less than 2.1 ng/ml, comprising less than 0.8%
of the mean CL-11 level (284 ng/ml) found in the 100 Danish
blood donors. Hence, the ELISA is not influenced by cross reactiv-
ity and is also suitable for identifying individuals with CL-11
polymorphisms and altered serum and plasma concentrations.
The two individuals affected by 3MC syndrome are homozygous
for the same CL-11 polymorphism, characterized by a single nu-
cleotide substitution, c.610 G>A, which results in the amino
acid substitution p.Gly204Ser in the carbohydrate recognition
domain (Rooryck et al., 2011). The observed deficiency suggests
that the substitution leads to retention or instability of CL-11.
During the submission of this paper, a study by Wakamiya and
colleagues reported an average CL-11 plasma concentration of
340±130 ng/ml in healthy Japanese donors using a combina-
tion of polyclonal- and monoclonal-based ELISA (Yoshizaki
et al., in press). These findings fall well in line with the mean
CL-11 concentration of 284 ng/ml measured in the Danish
blood donors. Mutations in the CL-11 and MASP-3 genes were
recently linked with the 3MC syndrome, and CL-11 and MASP-
3 were shown to play a role in embryonic developmental pro-
cesses. The functional role of CL-11 in innate immunity requires
further characterizations but the interaction with both MASP-1
and MASP-3 implies that it plays a role in the activation of the
complement system (Hansen et al., 2010). Recently, MASP-1
was shown to influence activation of factor D and activity of
the alternative pathway inmice (Takahashi et al., 2010). In sum-
mary, we have established a sandwich ELISA for measuring CL-
11 concentrations in human serum and plasma. The ELISA
enables evaluation of CL-11 levels in relation to diseases and
188 L. Selman et al. / Journal of Immunological Methods 375 (2012) 182–188syndromes. It is our hope that the ELISA and derived reagents
will allow for assessment of the functional role of CL-11.
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